CVRx secured Medicare Advantage coverage for its Barostim therapy from Devoted Health, effective July 17, 2026, marking a reimbursement win that broadens access

CVRx secured Medicare Advantage coverage for its Barostim therapy from Devoted Health, effective July 17, 2026, marking a reimbursement win that broadens access. Devoted is the eighth-largest MA insurer in the U.S.; Barostim targets heart failure.